SUBJECT: Biotech Bubble Hardens—Core AI Names Hold, Rotation to Big Pharma Intensifies
The Signal
The bifurcation isn't softening; it's accelerating. @biotech2k1 is now explicitly rotating out of early-stage biotech entirely, pivoting toward defensible mega-cap pharma ($GILD, $REGN, $ALNY) as the sector hits "most bubbly in a long time." Meanwhile, @adamfeuerstein's coverage of Genetix (formerly Bluebird Bio) post-distressed buyout signals that even distressed assets are being repositioned—legacy biotech with execution proof can re-rate, but the speculative cohort remains at structural risk from Anthropic-style AI incumbents entering drug discovery. The conviction names ($IOVA, $INSM, $BBIO) haven't moved off the list, but the macro positioning has shifted: informed capital is exiting the bubble before the reset, not during it.
What's Moving
- $GILD, $REGN, $ALNY — @biotech2k1 explicitly flagging as rotation targets from bubbly early-stage names. $GILD and $REGN offer scale + R&D moats; $ALNY near $300 on his buy list. Rationale: big pharma moats + dividend safety insulate from speculative unwind (via @biotech2k1)
- $IOVA — Still @crypto_condom's conviction name (via historical context); TIL-cell franchise with melanoma approved + NSCLC pivotal readout imminent. Competitive failures among peers reinforce moat. Holds thesis despite lack of fresh data this window.
- $INSM, $BBIO — @biotech2k1 remains on watch at $155 and $100 respectively. Deeper pipelines vs. bubble cohort provide insulation from single-drug risk. No fresh catalyst, but positioning unchanged through mid-cycle.
- Genetix (formerly $BBIO post-distressed buyout) — @adamfeuerstein coverage of CEO David Meek's swagger on sickle cell gene-therapy market dominance. Profitability claims vs. $VRTX/$CRSP/$BEAM competitive set. Execution on launch = key catalyst; patient access = real constraint (via @adamfeuerstein)
- Biotech bubble specs ($MIRM, $IMNM) — @biotech2k1 continues to view as high-dilution risk with no catalyst anchor. FOMO buying sub-$100, selling to euphoria remains the pattern. Avoid.
Crosscurrents
- $IOVA vs. broader TIL-cell competition — Two Phase 2/3 failures among peers (not IOVA) have reinforced IOVA's moat, but execution risk on NSCLC readout remains live. No hedging against clinical miss.
- Anthropic's drug entry + Genetix execution — Anthropic's $965B valuation + preclinical drug work signals structural displacement risk, yet Genetix's post-distressed buyout re-rating suggests legacy biotech with clinical proof can survive. The gap: do you have proof, or just hope?
Tradecraft
Desk Notes
- @biotech2k1 — Actively de-risking bubble exposure; rotating to $GILD/$REGN/$ALNY; flagged biotech as "most bubbly in a long time"; now ~75% cash equivalents ($SGOV).
- @adamfeuerstein — Tracking Genetix (distressed biotech re-rating) vs. competitive set; Orca Bio's T-cell approval signals private biotech execution paths.
- @crypto_condom — Holding $IOVA conviction despite volatility; TIL-cell moat thesis intact; noted $ABCL co-position.